Franklin Street Advisors’s Spyre Therapeutics SYRE Stock Holding History

Franklin Street Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,232	Closed	-$31K	–	159
2023 Q1	$31K	Hold	4,232	–	–	﹤0.01%	144
2022 Q4	$48K	Hold	4,232	–	–	﹤0.01%	143
2022 Q3	$56K	Hold	4,232	–	–	0.01%	138
2022 Q2	$53K	Hold	4,232	–	–	0.01%	147
2022 Q1	$243K	Hold	4,232	–	–	0.02%	139
2021 Q4	$503K	Buy	4,232 +88	+2%	+$13.9K	0.04%	110
2021 Q3	$824K	Hold	4,144	–	–	0.07%	90
2021 Q2	$721K	Hold	4,144	–	–	0.06%	92
2021 Q1	$821K	Buy	4,144 +1,204	+41%	+$231K	0.08%	87
2020 Q4	$578K	Hold	2,940	–	–	0.06%	99
2020 Q3	$521K	Buy	2,940 +940	+47%	+$174K	0.06%	95
2020 Q2	$463K	Buy	2,000 +600	+43%	+$114K	0.06%	96
2020 Q1	$163K	Buy	1,400 +200	+17%	+$34K	0.02%	127
2019 Q4	$229K	Hold	1,200	–	–	0.03%	139
2019 Q3	$231K	Hold	1,200	–	–	0.03%	139
2019 Q2	$206K	Hold	1,200	–	–	0.03%	150
2019 Q1	$242K	Buy	1,200 +400	+50%	+$83.4K	0.03%	131
2018 Q4	$150K	Buy	+800	New	+$170K	0.02%	137

Other funds holding SYRE

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Street Advisors's SYRE Position: Q2 2023 in Review

Franklin Street Advisors sold out of Spyre Therapeutics (SYRE) in Q2 2023, closing a stake of 4,232 shares — an estimated $31K sold.

Franklin Street Advisors first reported a position in SYRE in Q4 2018 and held it in 18 quarters. The position peaked at $824K in Q3 2021. 43 funds tracked by Wall St. Rank hold SYRE as of Q2 2023.

Franklin Street Advisors reported no remaining Spyre Therapeutics position as of Q2 2023 after selling out during the quarter.
Franklin Street Advisors sold 4,232 Spyre Therapeutics shares in Q2 2023, an estimated $31K.
Franklin Street Advisors first reported a position in Spyre Therapeutics in Q4 2018 and held it in 18 quarters.
Franklin Street Advisors's Spyre Therapeutics position peaked at $824K in Q3 2021.
43 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2023.

Based on Franklin Street Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.